Skip to main content
News

Want Better Odds? Get a Pharma Corporate VC to Invest – Forbes

By May 24, 2012No Comments
Pharma Investing

Pharma Investing

Pharma corporate venture was back in the biotech news today with the release of Burrill & Company’s June 2012 report.  An interesting article by Vinay Singh evaluated the impact of Pharma corporate venture capital (CVC) investing, and the key takeaway is that CVC-backed companies have a higher rate of overall success than those without their involvement.

While a similar takeway has been published before by Windhover’s StartUp about a year ago, these data suggests a fairly robust effect from a large dataset.  The analysis includes 2907 therapeutics companies that raised venture capital dollars between 2000-2010 across 5100 rounds of financing.  Corporate VCs were investors about 10% of companies, and this pool of 286 companies had what appears to be a markedly higher hit rate: a ~60% higher rate of licensing deals, M&As and IPOs. 

{iframe}http://www.forbes.com/sites/brucebooth/2012/05/22/want-better-odds-get-a-pharma-corporate-vc-to-invest/{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.